Stealth BioTherapeutics reports positive pre-clinical data for ALS candidate
Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
List view / Grid view
Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
A new phenomenon in the brain that could explain the development of early stages of neurodegeneration has been discovered which could lead to a future target for drug therapies for ALS.
Researchers have made discoveries about the formation of cellular components called membraneless organelles and the key role these organelles play in cells...
New approach for testing for ALS may be useful to reverse debilitating disease...
Drug delivery through the blood-brain barrier has shown to be difficult to overcome, but researchers may have discovered a method to overcome this issue...
Researchers have found another common thread linking nearly all of the TNR expansion diseases...